12:00 AM
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RO5024048: Phase IIb ongoing

Pharmasset said an IDMC recommended continuing enrollment of the 300-patient cohort in a double-blind, placebo-controlled, international Phase IIb trial evaluating oral RG7128 given twice daily in combination with Pegasys peginterferon alfa-2a and ribavirin. The decision was based on a review of safety...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >